Sellas Life Sciences Group, Inc. · NASDAQ:SLS
Sellas Life Sciences — Investor Presentation (January 2018)
29 slides from Sellas Life Sciences's investor presentation, Jan 5, 2018
Slide 1: Company Overview January 2018
Sellas LIFE SCIENCES Group, inc. Company OVERVIEW JANUARY 2018 Exhibit 99.3
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS This presentation may include forward-looking statements about strategy, future operations, future financial position, prospects, plans and objectives of SELLAS Life Sciences Group, Inc. (“SELLAS”). Examples of such statements include, but are not limited to, SELLAS’ abili
Slide 3: Executive Summary
EXECUTIVE SUMMARY YELLAS ili) ure sclENCES GROUP
Slide 4: Investment Highlights
investment Highlights: Late-stage immunotherapy company Lead asset, galinpepimut-S (GPS): numerous potential indications in a multibillion dollar cancer immunotherapy market Targets an NCI top ranked antigen, WT1 Highly differentiated, innovative technology, licensed from Memorial Sloan Kettering Ca
Slide 5: Clinical Overview
CLINICAL OVERVIEW GPS - an immunotherapy targeting the Wilms Tumor 1 (WT1) protein WT1 is a top-ranked cancer antigen target recognized by the National Cancer Institute Multivalent, heteroclitic technology targeting WT1 Exhibits strong immune response; ongoing development in monotherapy and combinat
Slide 6: Anticipated Milestones
ANTICIPATED MILESTONES Program Milestone Projected Date* Galinpepimut-S Updated data from Phase 2 multiple myeloma trial H1 2018 Galinpepimut-S Interim data from nivolumab combination trial in ovarian cancer H1 2018 NeuVax (nelipepimut-S) Interim data analysis: HER2 1+/2+ patients; combination trial
Slide 7: Partnerships & Collaborations
PARTNERSHIPS & collaborations
Slide 8: Galinpepimut-S Scientific Overview
GALINPEPIMUT-S SCIENTIFIC OVERVIEW
Slide 9: Wilms Tumor 1 Protein: A Top-Priority Target for Immunotherapy
Expressed broadly in hematological malignancies and solid tumors; not found appreciably in adult tissues, which lowers potential off-target toxicity Highest ranked target by National Cancer Institute project prioritizing cancer antigens for immunotherapy with the potential to treat 20 or more cancer
Slide 10: WT1: A Top Ranked Cancer Antigen by the NCI
AML: acute myelogenous leukemia; MPM: malignant pleural mesothelioma Tumor types pursued by SELLAS’ clinical program to-date Other tumor types Potential to treat 20 or more cancer types Expressed broadly in hematological malignancies and solid tumors 28/28 33/34 54/56 23/25 41/46 (Positive samples /
Slide 11: GPS Poised to Become an Effective Immunotherapy
GPS POISED TO BECOME AN EFFECTIVE immunotherapy Specificity across multiple HLA types and potentially applicable to 20+ cancer types Heteroclitic peptide increases immune response and mitigates tolerance, while maintaining antigenicity profile Also strengthens MHC class I and II binding for optimal
Slide 12: GPS: Immunogenicity Improved by Synthetic Heteroclitic Peptides
GPS: IMMUNOGENICITY IMPROVED BY CREATING SYNTHETIC HETEROCLITIC PEPTIDES Peptide Sequences (Position) Computationally Predicted Binding to HLA Immune Response WT1-A1: *YMFPNAPYL (126-134) A0201, A0301, A2402, B1501, B3901 CD8+ CTLs 427 long: RSDELVRHHNMHQRNMTKL (427-445) B1501, B3901, B0702, B08, B2
Slide 13: SELLAS Clinical Programs
SELLAS CLINICAL PROGRAMS YELLAS ili) ure sclENCES GROUP
Slide 14: Development Pipeline
PROGRAM PRECLINICAL PHASE 1 PHASE 2 PHASE 3 In-Licensed WT1 Delivery Technology NeuVax™ (nelipepimut-S) – Breast Cancer Development Programs Acute Myeloid Leukemia (AML) Phase 3 PLANNED* H2 ‘18 Phase 3 Protocol reviewed/approved by FDA; > 100 sites pre-screened DEVELOPMENT PIPELINE 14 Galinpepimut-S
Slide 15: Phase 2 Clinical Programs in Acute Myeloid Leukemia
Phase 2 study: primary endpoint met Primary objective of 3-year OS > 34% was met: 47.3% Key secondary objective to assess T-lymphocyte (CD8 and CD4) WT1-specific immune response Prolonged median overall survival: 67.6 months (all ages) Aggregate population of patients > 60 years (Phase 3 Population)
Slide 16: Phase 2 Trial in AML: Overall Survival in CR1
Source for historical controls: Walter RB, et al. J Clin Oncol. 2010; 28:1766-71. Source for historical controls: Freeman SD, et al. J Clin Oncol. 2013; 31:4123-31 phase 2 Trial in AML: Overall Survival in AML Patients in CR1 mOS from time of initial diagnosis = 35.3 mo mOS from CR1 = 34.0 mo mOS =
Slide 17: Phase 2 Trial in AML vs. Historical Comparators
phase 2 Trial in AML: AML Patients > 60 year (in CR1) Study Results vs. Historical comparators Additional Comparisons for Landmark 2-year OS Rates 61% PHASE 2 SURVIVAL WITH GPS IN THE POPULATION TARGETED BY SELLAS’ PHASE 3 TRIAL EXCEEDS THAT SEEN WITH HISTORICAL COMPARATORS, EVEN ALLOGENEIC STEM CEL
Slide 18: Independent Trial in AML Patients in CR2 at Moffitt
Brayer, Am J Hematol. 2015 Independent trial at the Moffit Cancer Center (MCC; Tampa, FL) in patients after second complete remission (CR2) AML patients receiving > 2 administrations of GPS (n=10) compared to group of paired patients in CR2 contemporaneously treated at MCC during a similar time peri
Slide 19: Phase 2 Randomized Trial in Malignant Pleural Mesothelioma
Controlled, randomized blinded Phase 2 study with GPS after upfront surgery and other treatment (n=41) GPS increased overall survival (OS) vs. control group Median overall survival: 22.8 vs. 18.3 months (HR: 0.79) Median overall survival for patients with complete resection (R0/1): 22.8 vs. 16.6 mon
Slide 20: Phase 2 Multiple Myeloma Study
Phase 2, open-label study of GPS in myeloma patients following autologous stem cell transplant (SCT) Patients were treated for up to 9 months (12 GPS administrations) 15/18 patients had high-risk cytogenetics at baseline; all patients remained at least MRD(+) after SCT This type of MM patients typic
Slide 21: Phase 2 Multiple Myeloma Study: Progression-Free Survival
*Rawstron A. J Clin Oncol. 2013 15/18 evaluable patients: high-risk cytogenetics MRC IX Trial* Highlights potential benefit of gps in phase 2 trial 88% overall survival at 18 months; Median OS not yet reached Event Probability Time (months) 21 24 N = 18(2) Best Available Therapy N = 42 Galinpepimut-
Slide 22: Planned Phase 3 Study in AML
Successful End-of-Phase 2 Meeting with FDA Agreed upon development, study design, endpoints, statistical analysis and CMC Primary endpoint is overall survival; secondary endpoints include LFS, safety/MRD, immune response 180 sites in North America, Europe, Australia/New Zealand, Asia; > 100 sites al
Slide 23: Planned GPS + Pembrolizumab Phase 2A Study
Open label, multicenter, multi-arm combination trial; N = 90 Schema Adult patients (>18 yrs) with confirmed WT1 expression (by IHC) Presence of technically biopsiable lesions CRC: tumor samples genomically tested for microsatellite status (MSS vs MSI) ENROLLMENT Galinpepimut-S (200 µg/ peptide x 4 à
Slide 24: Corporate
CORPORATE YELLAS ili) ure sclENCES GROUP
Slide 25: Management Team
MANAGEMENT TEAM NAME POSITION PRIOR EXPERIENCE / AFFILIATIONS Angelos Stergiou, M.D., ScD h.c. Chief Executive Officer Nicholas J. Sarlis, M.D., Ph.D., FACP Chief Medical Officer Aleksey Krylov, CFA Chief Financial Officer (Interim) Gregory M. Torre, Ph.D., J.D. Chief Regulatory Officer SVP, Technic
Slide 26: Board of Directors
BOARD OF DIRECTORS NAME POSITION PRIOR EXPERIENCE / AFFILIATIONS Jane Wasman Board Chair, Nominating and Governance Committee Chair Angelos Stergiou, MD, ScD h.c. Chief Executive Officer John Varian Audit Committee Chair Robert Van Nostrand Compensation Committee Chair Dr. David Scheinberg Science C
Slide 27: Scientific Advisory Board
SCIENTIFIC ADVISORY BOARD NAME POSITION Jedd D. Wolchok, M.D., Ph.D. Chief, Melanoma & Immunotherapeutics Service at Memorial Sloan Kettering Cancer Center (MSKCC) Jeffrey Weber, M.D., Ph.D. Deputy Director of the Perlmutter Cancer Center, Co-director of the Melanoma Research Program at the New York
Slide 28: Financial Summary
FINANCIAL SUMMARY (1) As of 1/3/2018, market close (2) As of 9/30/2017, pro-forma combined Reverse Merger Closed 12/29/2017 NASDAQ: SLS – Trading Commenced 1/2/2018 Common Shares Outstanding: 5.8 M (1) Warrants/Options/RSUs: 0.9 M (1) Cash: $15.3 M (2)
Slide 29: Company Overview January 2018
Sellas LIFE SCIENCES group, inc. Company OVERVIEW JANUARY 2018
SELLAS Life Sciences Group — Investor Presentation (January 2018) on 6ix